Meeting
2016 ASCO Annual Meeting
Nomograms to predict the presence of EGFR mutations and ALK rearrangements in non-small-cell lung carcinoma.
Authors
Wenfeng Fang
Cancer Center, Sun Yat-Sen University, Guangzhou, China
Wenfeng Fang , Shaodong Hong , Yunpeng Yang , Yuxiang Ma , Yuangyuan Zhao , Hongyun Zhao , Yan Huang , Li Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention, Genetics, and Epidemiology
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 34, 2016 (suppl; abstr 1587)
DOI
10.1200/JCO.2016.34.15_suppl.1587
Abstract #
1587
Poster Bd #
410
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
ALK rearrangement in a selected population of advanced non small cell lung cancer patients. FISH and inmunohistochemistry diagnostic methods, prevalence and clinical outcomes.
First Author: P. Martinez
Poster
2020 ASCO Virtual Scientific Program
A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).
First Author: Sehhoon Park
Poster
2014 ASCO Annual Meeting
Molecular testing prior to first-line therapy in patients with stage IV nonsquamous non-small cell lung cancer (NSCLC): A survey of U.S. medical oncologists.
First Author: Mark R. Green
Poster
2024 ASCO Annual Meeting
Development of clinically accessible nomograms to predict risk of brain metastases at baseline and follow-up in patients with non-small cell lung cancer.
First Author: Alireza Mansouri